RxDoctor Payments Data

Thomas Jones, MD

Ophthalmology · Everett, WANPI 1205195641

Payments from drug & device makers

$859in general payments, 2019–2025

Across 30 payments — averaging $28.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$194
  • Abbott$151
  • Alcon$100
  • Tarsus Pharmaceuticals, Inc.$85
  • AbbVie$60
  • Rxsight Inc$43
  • plus $226 from 8 others

What the payments were for

  • Food & beverage$859100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$859 in reported general payments places this provider in the 50th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$196,746
Medicare patients
517
Services billed
1,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine28$35,275
TyrvayaVarenicline Tartrate27$28,920
RocklatanNetarsudil Mesylat/Latanoprost32$21,707
LumiganBimatoprost15$11,229
Prednisolone Acetate203$6,355
Latanoprost366$5,322
SimbrinzaBrinzolamide/Brimonidine Tart17$4,917
Ketorolac Tromethamine170$4,173
MoxifloxacinMoxifloxacin Hcl168$3,737
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat192$3,010
Timolol Maleate118$2,473
Fluorometholone30$2,065
Loteprednol Etabonate15$1,727
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol16$1,726
Dorzolamide-TimololDorzolamide/Timolol/Pf12$1,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$60$46,50443 claims
Oyster Point Pharma, Inc.Tyrvaya$29$28,92027 claims
AlconSimbrinza$100$4,91717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Everett

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →